

## • **A compendium of single extracellular vesicle flow cytometry**

<b>Type</b>	Article de revue
<b>Auteur</b>	Joshua A. Welsh
<b>Auteur</b>	Ger J. A. Arkesteijn
<b>Auteur</b>	Michel Bremer
<b>Auteur</b>	Michael Cimorelli
<b>Auteur</b>	Françoise Dignat-George
<b>Auteur</b>	Bernd Giebel
<b>Auteur</b>	André Görgens
<b>Auteur</b>	An Hendrix
<b>Auteur</b>	Martine Kuiper
<b>Auteur</b>	Romaric Lacroix
<b>Auteur</b>	Joanne Lannigan
<b>Auteur</b>	Ton G. van Leeuwen
<b>Auteur</b>	Estefanía Lozano-Andrés
<b>Auteur</b>	Shoaib Rao
<b>Auteur</b>	Stéphane Robert
<b>Auteur</b>	Leonie de Rond
<b>Auteur</b>	Vera A. Tang
<b>Auteur</b>	Tobias Tertel
<b>Auteur</b>	Xiaomei Yan
<b>Auteur</b>	Marca H. M. Wauben
<b>Auteur</b>	John P. Nolan
<b>Auteur</b>	Jennifer C. Jones
<b>Auteur</b>	Rienk Nieuwland
<b>Auteur</b>	Edwin van der Pol

### **Résumé**

Flow cytometry (FCM) offers a multiparametric technology capable of characterizing single extracellular vesicles (EVs). However, most flow cytometers are designed to detect cells, which are larger than EVs. Whereas cells exceed the background noise, signals originating from EVs partly overlap with the background noise, thereby making EVs more difficult to detect than cells. This technical mismatch together with complexity of EV-containing fluids causes limitations and challenges with conducting, interpreting and reproducing EV FCM experiments. To address and overcome these challenges, researchers from the International Society for Extracellular Vesicles (ISEV), International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH) joined forces and initiated the EV FCM working group. To improve the interpretation, reporting, and reproducibility of future EV FCM data, the EV FCM working group published an ISEV position manuscript outlining a framework of minimum information that should be reported about an

FCM experiment on single EVs (MIFlowCyt-EV). However, the framework contains limited background information. Therefore, the goal of this compendium is to provide the background information necessary to design and conduct reproducible EV FCM experiments. This compendium contains background information on EVs, the interaction between light and EVs, FCM hardware, experimental design and preanalytical procedures, sample preparation, assay controls, instrument data acquisition and calibration, EV characterization, and data reporting. Although this compendium focuses on EVs, many concepts and explanations could also be applied to FCM detection of other particles within the EV size range, such as bacteria, lipoprotein particles, milk fat globules, and viruses.

**Date** 2023  
**Langue** en  
**Catalogue de bibl.** Wiley Online Library  
**URL** <http://onlinelibrary.wiley.com/doi/abs/10.1002/jev2.12299>  
**Consulté le** 20/02/2023 à 11:42:21  
**Extra** \_eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/jev2.12299>  
**Volume** 12  
**Pages** e12299  
**Publication** Journal of Extracellular Vesicles  
**DOI** [10.1002/jev2.12299](https://doi.org/10.1002/jev2.12299)  
**Numéro** 2  
**ISSN** 2001-3078  
**Date d'ajout** 20/02/2023 à 11:42:21  
**Modifié le** 20/02/2023 à 11:42:21

- **Marqueurs :**
  - extracellular vesicles
  - microparticles
  - standardization
  - nanoparticles
  - flow cytometry
  - calibration
  - MIFlowCyt-EV

#### **Pièces jointes**

- Full Text PDF
- Snapshot
- **A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance**

**Type** Article de revue  
**Auteur** Sylvie Cointe  
**Auteur** Karim Harti Souab  
**Auteur** Tarik Bouriche  
**Auteur** Loris Vallier  
**Auteur** Amandine Bonifay  
**Auteur** Coralie Judicone  
**Auteur** Stéphane Robert  
**Auteur** Romain Armand  
**Auteur** Philippe Poncelet  
**Auteur** Jacques Albanese  
**Auteur** Françoise Dignat-George  
**Auteur** Romaric Lacroix

**Résumé** Among extracellular vesicles, leukocyte-derived microvesicles (LMVs) have emerged as complex vesicular structures. Primarily identified as procoagulant entities, they were more recently ascribed to plasmin generation capacity (MV-PGC). The objectives of this work were (1) to develop a new hybrid bio-assay combining the specific isolation of LMVs and measurement of their PGC, and compare its performance to the original method based on centrifugation, (2) to validate MV-PGC in septic shock, combining increased levels of LMVs and fibrinolytic imbalance. Using plasma sample spiked with LMVs featuring different levels of PGC, we demonstrated that CD15-beads specifically extracted LMVs. The MV dependency of the test was demonstrated using electron microscopy, high speed centrifugation, nanofiltration and detergent-mediated solubilization and the MV-PGC specificity using plasmin-specific inhibitors, or antibodies blocking elastase or uPA. Thanks to a reaction booster ( $\epsilon$ -ACA), we showed that the assay was more sensitive and reproducible than the original method. Moreover, it exhibited a good repeatability, inter-operator and inter-experiment reproducibility. The new immunomagnetic bio-assay was further validated in patients with septic shock. As a result, we showed that MV-PGC values were significantly lower in septic shock patients who died compared to patients who survived, both at inclusion and 24 h later (1.4 [0.8-3.0] vs 3.1 [1.7-18]  $A_{405} \times 10^{-3}/\text{min}$ ,  $p = 0.02$ ; 1.4 [1-1.6] vs 5.2 [2.2-16]  $A_{405} \times 10^{-3}/\text{min}$ ,  $p = 0.004$ ). Interestingly, combining both MV-PGC and PAI-1 in a ratio significantly improved the predictive value of PAI-1. This strategy, a hybrid capture bioassay to specifically measure LMV-PGC using for the first time, opens new perspectives for measuring subcellular fibrinolytic potential in clinical settings with fibrinolytic imbalance.

**Date** 2018  
**Langue** eng  
**Titre abrégé** A new assay to evaluate microvesicle plasmin generation capacity

**Catalogue de bibl.** PubMed  
**Extra** Number: 1  
**Volume** 7  
**Pages** 1494482  
**Publication** Journal of Extracellular Vesicles  
**DOI** [10.1080/20013078.2018.1494482](https://doi.org/10.1080/20013078.2018.1494482)  
**Numéro** 1  
**Abrév. de revue** J Extracell Vesicles  
**ISSN** 2001-3078  
**Date d'ajout** 13/12/2021 à 10:35:05  
**Modifié le** 13/12/2021 à 10:35:05

- **Marqueurs :**
  - extracellular vesicles
  - Fibrinolysis
  - Microvesicles
  - immunomagnetic separation
  - septic shock

#### **Pièces jointes**

- PubMed entry
- Texte intégral
- **A new strategy to count and sort neutrophil-derived extracellular vesicles: Validation in infectious disorders**

**Type** Article de revue  
**Auteur** Amandine Bonifay  
**Auteur** Stéphane Robert  
**Auteur** Belinda Champagne  
**Auteur** Paul-Rémi Petit  
**Auteur** Aude Eugène  
**Auteur** Corinne Chareyre  
**Auteur** Anne-Claire Duchez  
**Auteur** Mélanie Véliér  
**Auteur** Shirley Fritz  
**Auteur** Loris Vallier  
**Auteur** Romaric Lacroix  
**Auteur** Françoise Dignat-George

**Résumé**

Newly recognized polymorphonuclear neutrophil (PMNs) functions include the ability to release subcellular mediators such as neutrophil-derived extracellular vesicles (NDEVs) involved in immune and thrombo-inflammatory responses. Elevation of their plasmatic level has been reported in a variety of infectious and cardiovascular disorders, but the clinical use of this potential biomarker is hampered by methodological issues. Although flow cytometry (FCM) is currently used to detect NDEVs in the plasma of patients, an extensive characterization of NDEVs has never been done. Moreover, their detection remains challenging because of their small size and low antigen density. Therefore, the objective of the present study was first to establish a surface antigenic signature of NDEVs detectable by FCM and therefore to improve their detection in biological fluids by developing a strategy allowing to overcome their low fluorescent signal and reduce the background noise. By testing a large panel of 54 antibody specificities already reported to be positive on PMNs, we identified a profile of 15 membrane protein markers, including 4 (CD157, CD24, CD65 and CD66c) never described on NDEVs. Among them, CD15, CD66b and CD66c were identified as the most sensitive and specific markers to detect NDEVs by FCM. Using this antigenic signature, we developed a new strategy combining the three best antibodies in a cocktail and reducing the background noise by size exclusion chromatography (SEC). This strategy allowed a significant improvement in NDEVs enumeration in plasma from sepsis patients and made it feasible to efficiently sort NDEVs from COVID-19 patients. Altogether, this work opens the door to a more valuable measurement of NDEVs as a potential biomarker in clinical practice. A similar strategy could also be applied to improve detection by FCM of other rare subpopulations of EVs generated by tissues with limited access, such as vascular endothelium, cancer cells or placenta.

**Date** 2022  
**Langue** en  
**Titre abrégé** A new strategy to count and sort neutrophil-derived extracellular vesicles  
**Catalogue de bibl.** Wiley Online Library  
**URL** <https://onlinelibrary.wiley.com/doi/abs/10.1002/jev2.12204>  
**Consulté le** 01/04/2022 à 15:43:11  
**Extra** \_eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/jev2.12204>  
**Volume** 11  
**Pages** e12204  
**Publication** Journal of Extracellular Vesicles  
**DOI** [10.1002/jev2.12204](https://doi.org/10.1002/jev2.12204)  
**Numéro** 4  
**ISSN** 2001-3078  
**Date d'ajout** 01/04/2022 à 15:43:11

Modifié le 01/04/2022 à 15:43:11

- **Marqueurs :**
  - extracellular vesicles
  - flow cytometry
  - EVs sorting
  - infectious associated diseases
  - neutrophils
  - size exclusion chromatography

### **Pièces jointes**

- Full Text PDF
- Snapshot

- **A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule**

**Type** Article de revue  
**Auteur** Marie Nollet  
**Auteur** Jimmy Stalin  
**Auteur** Anaïs Moyon  
**Auteur** Waël Traboulsi  
**Auteur** Amel Essaadi  
**Auteur** Stéphane Robert  
**Auteur** Nausicaa Malissen  
**Auteur** Richard Bachelier  
**Auteur** Laurent Daniel  
**Auteur** Alexandrine Foucault-Bertaud  
**Auteur** Caroline Gaudy-Marqueste  
**Auteur** Romaric Lacroix  
**Auteur** Aurélie S. Leroyer  
**Auteur** Benjamin Guillet  
**Auteur** Nathalie Bardin  
**Auteur** Françoise Dignat-George  
**Auteur** Marcel Blot-Chabaud

**Résumé** CD146 is an adhesion molecule present on many tumors (melanoma, kidney, pancreas, breast, ...). In addition, it has been shown to be expressed on vascular endothelial and smooth muscle cells. Generating an antibody able to specifically recognize CD146 in cancer cells (designated as tumor CD146), but not in normal cells, would thus be of major interest for targeting tumor CD146 without affecting the vascular system. We thus generated antibodies against the extracellular domain of the molecule produced in cancer cells and selected an antibody that specifically recognizes tumor CD146. This antibody (TsCD146 mAb)

was able to detect CD146-positive tumors in human biopsies and in vivo, by PET imaging, in a murine xenograft model. In addition, TsCD146 mAb antibody was able to specifically detect CD146-positive cancer microparticles in the plasma of patients. TsCD146 mAb displayed also therapeutic effects since it was able to reduce the growth of human CD146-positive cancer cells xenografted in nude mice. This effect was due to a decrease in the proliferation and an increase in the apoptosis of CD146-positive cancer cells after TsCD146-mediated internalization of the cell surface CD146. Thus, TsCD146 mAb could be of major interest for diagnostic and therapeutic strategies against CD146-positive tumors in a context of personalized medicine.

**Date** Dec 22, 2017  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** Number: 68  
**Volume** 8  
**Pages** 112283-112296  
**Publication** Oncotarget  
**DOI** [10.18632/oncotarget.22736](https://doi.org/10.18632/oncotarget.22736)  
**Numéro** 68  
**Abrév. de revue** Oncotarget  
**ISSN** 1949-2553  
**Date d'ajout** 13/12/2021 à 10:35:05  
**Modifié le** 13/12/2021 à 10:35:05

- **Marqueurs :**
  - antibody
  - cancer
  - CD146
  - PET
  - therapy

#### **Pièces jointes**

- PubMed entry
- Texte intégral
- **Biogenesis of Pro-senescent Microparticles by Endothelial Colony Forming Cells from Premature Neonates is driven by SIRT1-Dependent Epigenetic Regulation of MKK6**

**Type** Article de revue

**Auteur** Stéphanie Simoncini  
**Auteur** Anne-Line Chateau  
**Auteur** Stéphane Robert  
**Auteur** Dilyana Todorova  
**Auteur** Catherine Yzydorick  
**Auteur** Romaric Lacroix  
**Auteur** Isabelle Ligi  
**Auteur** Laurence Louis  
**Auteur** Richard Bachelier  
**Auteur** Umberto Simeoni  
**Auteur** Frédérique Magdinier  
**Auteur** Françoise Dignat-George  
**Auteur** Florence Sabatier

**Résumé** Senescent cells may exert detrimental effect on microenvironment through the secretion of soluble factors and the release of extracellular vesicles, such as microparticles, key actors in ageing and cardiovascular diseases. We previously reported that sirtuin-1 (SIRT1) deficiency drives accelerated senescence and dysfunction of endothelial colony-forming cells (ECFC) in PT neonates. Because preterm birth (PT) increases the risk for cardiovascular diseases during neonatal period as well as at adulthood, we hypothesized that SIRT1 deficiency could control the biogenesis of microparticles as part of a senescence-associated secretory phenotype (SASP) of PT-ECFC and investigated the related molecular mechanisms. Compared to control ECFC, PT-ECFC displayed a SASP associated with increased release of endothelial microparticles (EMP), mediating a paracrine induction of senescence in naïve endothelial cells. SIRT1 level inversely correlated with EMP release and drives PT-ECFC vesiculation. Global transcriptomic analysis revealed changes in stress response pathways, specifically the MAPK pathway. We delineate a new epigenetic mechanism by which SIRT1 deficiency regulates MKK6/p38MAPK/Hsp27 pathway to promote EMP biogenesis in senescent ECFC. These findings deepen our understanding of the role of ECFC senescence in the disruption of endothelial homeostasis and provide potential new targets towards the control of cardiovascular risk in individuals born preterm.

**Date** 08 15, 2017  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** Number: 1  
**Volume** 7  
**Pages** 8277  
**Publication** Scientific Reports  
**DOI** [10.1038/s41598-017-08883-1](https://doi.org/10.1038/s41598-017-08883-1)

**Numéro** 1  
**Abrév. de revue** Sci Rep  
**ISSN** 2045-2322  
**Date d'ajout** 13/12/2021 à 10:35:05  
**Modifié le** 13/12/2021 à 10:35:05

• **Marqueurs :**

- Humans
- Models, Biological
- Cell-Derived Microparticles
- Endothelial Cells
- Signal Transduction
- Cellular Senescence
- Gene Expression Profiling
- Transcriptome
- Gene Expression Regulation
- Endothelial Progenitor Cells
- Epigenesis, Genetic
- Gene Deletion
- Infant, Newborn
- MAP Kinase Kinase 6
- p38 Mitogen-Activated Protein Kinases
- Paracrine Communication
- Premature Birth
- Sirtuin 1

**Pièces jointes**

- PubMed entry
- Texte intégral

• **CD146 deficiency promotes plaque formation in a mouse model of atherosclerosis by enhancing RANTES secretion and leukocyte recruitment**

**Type** Article de revue  
**Auteur** Muriel G. Blin  
**Auteur** Richard Bachelier  
**Auteur** Karim Fallague  
**Auteur** Karima Moussouni  
**Auteur** Michel Aurrand-Lions  
**Auteur** Samantha Fernandez  
**Auteur** Benjamin Guillet  
**Auteur** Stéphane Robert  
**Auteur** Alexandrine Foucault-Bertaud

**Auteur** Nathalie Bardin  
**Auteur** Marcel Blot-Chabaud  
**Auteur** Françoise Dignat-George  
**Auteur** Aurélie S. Leroyer

**Résumé** AIMS: The progression of atherosclerosis is based on the continued recruitment of leukocytes in the vessel wall. The previously described role of CD146 in leukocyte infiltration suggests an involvement for this adhesion molecule in the inflammatory response. In this study, we investigated the role of CD146 in leukocyte recruitment by using an experimental model of atherogenesis. **METHODS AND RESULTS:** The role of CD146 was explored in atherosclerosis by crossing CD146<sup>-/-</sup> mice with ApoE<sup>-/-</sup> mice. CD146<sup>-/-</sup>/ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup> mice were fed a Western diet for 24 weeks and were monitored for aortic wall thickness using high frequency ultrasound. The arterial wall was significantly thicker in CD146-deficient mice. After 24 weeks of Western diet, a significant increase of atheroma in both total aortic lesion and aortic sinus of CD146-null mice was observed. In addition, atherosclerotic lesions were more inflammatory since plaques from CD146-deficient mice contained more neutrophils and macrophages. This was due to up-regulation of RANTES secretion by macrophages in CD146-deficient atherosclerotic arteries. This prompted us to further address the function of CD146 in leukocyte recruitment during acute inflammation by using a second experimental model of peritonitis induced by thioglycollate. Neutrophil recruitment was significantly increased in CD146-deficient mice 12 h after peritonitis induction and associated with higher RANTES levels in the peritoneal cavity. In CD146-null macrophages, we also showed that increased RANTES production was dependent on constitutive inhibition of the p38-MAPK signaling pathway. Finally, Maraviroc, a RANTES receptor antagonist, was able to reduce atherosclerotic lesions and neutrophilia in CD146-deficient mice to the same level as that found in ApoE<sup>-/-</sup> mice. **CONCLUSIONS:** Our data indicate that CD146 deficiency is associated with the upregulation of RANTES production and increased inflammation of atheroma, which could influence the atherosclerotic plaque fate. Thus, these data identify CD146 agonists as potential new therapeutic candidates for atherosclerosis treatment.

**Date** 05 2019  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Volume** 130  
**Pages** 76-87  
**Publication** Journal of Molecular and Cellular Cardiology  
**DOI** [10.1016/j.yjmcc.2019.03.017](https://doi.org/10.1016/j.yjmcc.2019.03.017)  
**Abrév. de revue** J. Mol. Cell. Cardiol.  
**ISSN** 1095-8584

**Date d'ajout** 13/12/2021 à 10:35:04  
**Modifié le** 13/12/2021 à 10:35:04

- **Pièces jointes**
  - PubMed entry
  - Version soumise
- **Extracellular vesicles from T cells overexpress miR-146b-5p in HIV-1 infection and repress endothelial activation**

**Type** Article de revue  
**Auteur** Estelle Balducci  
**Auteur** Aurélie S. Leroyer  
**Auteur** Romaric Lacroix  
**Auteur** Stéphane Robert  
**Auteur** Dilyana Todorova  
**Auteur** Stéphanie Simoncini  
**Auteur** Luc Lyonnet  
**Auteur** Corinne Chareyre  
**Auteur** Olivia Zaegel-Faucher  
**Auteur** Joëlle Micallef  
**Auteur** Isabelle Poizot-Martin  
**Auteur** Patrice Roll  
**Auteur** Françoise Dignat-George

**Résumé** Human immunodeficiency virus type 1 (HIV-1) infection promotes a generalized activation of host responses that involves not only CD4 T cells, but also cells of the microenvironment, which are not directly infected, such as endothelial cells. The mechanisms triggering HIV-1-associated vascular alterations remain poorly understood. Extracellular vesicles (EVs), implicated in cell-to-cell communication, have been recently described as carriers of microRNAs (miRNAs). Here, we show that miR-146b-5p is upregulated in both CD4 T cells, CD4 T cell-derived EVs and circulating EVs obtained from antiretroviral therapy-naïve HIV-1-infected patients. We further demonstrate that EVs from T cell line overexpressing miR-146b-5p mimics (miR-146b-EVs): 1) protect their miRNA cargo from RNase degradation, 2) transfer miR-146b-5p mimics into endothelial cells and 3) reduce endothelial inflammatory responses in vitro and in vivo in the lungs of mice through the downregulation of nuclear factor- $\kappa$ B-responsive molecules. These data advance our understanding on chronic inflammatory responses affecting endothelial homeostasis, in infectious and non-infectious diseases and pave the way for potential new anti-inflammatory strategies.

**Date** 07 16, 2019

**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** Number: 1  
**Volume** 9  
**Pages** 10299  
**Publication** Scientific Reports  
**DOI** [10.1038/s41598-019-44743-w](https://doi.org/10.1038/s41598-019-44743-w)  
**Numéro** 1  
**Abrév. de revue** Sci Rep  
**ISSN** 2045-2322  
**Date d'ajout** 13/12/2021 à 10:34:50  
**Modifié le** 13/12/2021 à 10:34:50

- **Pièces jointes**
  - PubMed entry
  - Texte intégral
- **Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock**

**Type** Article de revue  
**Auteur** Sylvie Cointe  
**Auteur** Loris Vallier  
**Auteur** Pierre Esnault  
**Auteur** Mathilde Dacos  
**Auteur** Amandine Bonifay  
**Auteur** Nicolas Macagno  
**Auteur** Karim Harti Souab  
**Auteur** Corinne Chareyre  
**Auteur** Coralie Judicone  
**Auteur** Diane Frankel  
**Auteur** Stephane Robert  
**Auteur** Sami Hraiech  
**Auteur** Marie-Christine Alessi  
**Auteur** Philippe Poncelet  
**Auteur** Jacques Albanese  
**Auteur** Françoise Dignat-George  
**Auteur** Romaric Lacroix  
**Résumé** Microvesicles (MVs) have previously been shown to exert profibrinolytic capacity, which is increased in patients with septic

shock (SS) with a favorable outcome. We therefore hypothesized that the plasmin generation capacity (PGC) could confer to MVs a protective effect supported by their capacity to lyse a thrombus, and we investigated the mechanisms involved. Using a MV-PGC kinetic assay, ELISA and flow cytometry, we found that granulocyte MVs (Gran-MVs) from SS patients display a heterogeneous PGC profile driven by the uPA (urokinase)/uPAR system. In vitro, these MVs lyse a thrombus according to their MV-PGC levels in a uPA/uPAR-dependent manner, as shown in a fluorescent clot lysis test and a lysis front retraction assay. Fibrinolytic activators conveyed by MVs contribute to approximately 30% of the plasma plasminogenolytic capacity of SS patients. In a murine model of SS, the injection of high PGC Gran-MVs significantly improved mouse survival and reduced the number of thrombi in vital organs. This was associated with a modification of the mouse coagulation and fibrinolysis properties toward a more fibrinolytic profile. Interestingly, mouse survival was not improved when soluble uPA was injected. Finally, using a multiplex array on plasma from SS patients, we found that neutrophil elastase correlates with the effect of high-PGC-capacity plasma and modulates the Gran-MV plasmin generation capacity by cleaving uPA-PAI-1 complexes. In conclusion, we show that high PGC level displayed by Gran-MVs reduce thrombus formation and improve survival conferring to Gran-MVs a protective role in a murine model of sepsis.

**Date** 2022-01-13  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** PMID: 35026004  
**Pages** blood.2021013328  
**Publication** Blood  
**DOI** [10.1182/blood.2021013328](https://doi.org/10.1182/blood.2021013328)  
**Abrév. de revue** Blood  
**ISSN** 1528-0020  
**Date d'ajout** 17/01/2022 à 17:30:44  
**Modifié le** 17/01/2022 à 17:30:44

- **Pièces jointes**
  - PubMed entry
- **Immune thrombotic thrombocytopenic purpura plasmas induce calcium- and IgG-dependent endothelial activation: correlations with disease severity**

**Type** Article de revue

**Auteur** Edwige Tellier  
**Auteur** Agnès Widemann  
**Auteur** Raphaël Cauchois  
**Auteur** Julien Faccini  
**Auteur** Marie Lagarde  
**Auteur** Marion Brun  
**Auteur** Philippe Robert  
**Auteur** Stéphane Robert  
**Auteur** Richard Bachelier  
**Auteur** Pascale Poullin  
**Auteur** Elien Roose  
**Auteur** Karen Vanhoorelbeke  
**Auteur** Paul Coppo  
**Auteur** Françoise Dignat-George  
**Auteur** Gilles Kaplanski

**Résumé** Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by a severe ADAMTS13 deficiency due to the presence of anti-ADAMTS13 autoantibodies, with subsequent accumulation of circulating ultra-large von Willebrand Factor (VWF) multimers. The role of endothelial cell activation as a trigger of the disease has been suggested in animal models but remains to be demonstrated in humans. We prospectively obtained plasma from the first plasma exchange of 25 patients during iTTP acute phase. iTTP but not control plasma, induced a rapid VWF release and P-selectin exposure on dermal human microvascular endothelial cell (HMVEC-d) surface, associated with angiopoietin-2 and endothelin-1 secretion, consistent with Weibel-Palade bodies exocytosis. Calcium (Ca<sup>2+</sup>) blockade significantly decreased VWF release, whereas iTTP plasma induced a rapid and sustained Ca<sup>2+</sup> flux in HMVEC-d which correlated in retrospect, with disease severity and survival in 62 iTTP patients. F(ab)<sub>2</sub> fragments purified from the immunoglobulin G (IgG) fraction of iTTP plasma mainly induced endothelial cell (EC) activation with additional minor roles for circulating free heme and nucleosomes, but not for complement. Furthermore, two anti-ADAMTS13 monoclonal antibodies purified from iTTP patient B cells, but not serum from hereditary TTP, induced endothelial Ca<sup>2+</sup> flux associated with Weibel-Palade bodies exocytosis in vitro, whereas inhibition of endothelial ADAMTS13 expression using small interference RNA, significantly decreased the stimulating effects of iTTP IgG. In conclusion, Ca<sup>2+</sup>-mediated endothelial cell activation constitutes a second "hit" of iTTP, is correlated with the severity of the disease and may constitute a possible therapeutic target.

**Date** 2022-12-01

**Langue** eng

**Titre abrégé** Immune thrombotic thrombocytopenic purpura plasmas induce calcium- and IgG-dependent endothelial activation

**Catalogue de bibl.** PubMed  
**Extra** PMID: 36453103  
**Publication** Haematologica  
**DOI** [10.3324/haematol.2022.280651](https://doi.org/10.3324/haematol.2022.280651)  
**Abrév. de revue** Haematologica  
**ISSN** 1592-8721  
**Date d'ajout** 12/01/2023 à 09:19:06  
**Modifié le** 12/01/2023 à 09:19:06

- **Pièces jointes**
  - PubMed entry
  - Texte intégral
- **MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments**

**Type** Article de revue  
**Auteur** Joshua A. Welsh  
**Auteur** Edwin Van Der Pol  
**Auteur** Ger J. A. Arkesteijn  
**Auteur** Michel Bremer  
**Auteur** Alain Brisson  
**Auteur** Frank Coumans  
**Auteur** Françoise Dignat-George  
**Auteur** Erika Duggan  
**Auteur** Ionita Ghiran  
**Auteur** Bernd Giebel  
**Auteur** André Görgens  
**Auteur** An Hendrix  
**Auteur** Romaric Lacroix  
**Auteur** Joanne Lannigan  
**Auteur** Sten F. W. M. Libregts  
**Auteur** Estefanía Lozano-Andrés  
**Auteur** Aizea Morales-Kastresana  
**Auteur** Stephane Robert  
**Auteur** Leonie De Rond  
**Auteur** Tobias Tertel  
**Auteur** John Tigges  
**Auteur** Olivier De Wever

**Auteur** Xiaomei Yan  
**Auteur** Rienk Nieuwland  
**Auteur** Marca H. M. Wauben  
**Auteur** John P. Nolan  
**Auteur** Jennifer C. Jones

**Résumé** Extracellular vesicles (EVs) are small, heterogeneous and difficult to measure. Flow cytometry (FC) is a key technology for the measurement of individual particles, but its application to the analysis of EVs and other submicron particles has presented many challenges and has produced a number of controversial results, in part due to limitations of instrument detection, lack of robust methods and ambiguities in how data should be interpreted. These complications are exacerbated by the field's lack of a robust reporting framework, and many EV-FC manuscripts include incomplete descriptions of methods and results, contain artefacts stemming from an insufficient instrument sensitivity and inappropriate experimental design and lack appropriate calibration and standardization. To address these issues, a working group (WG) of EV-FC researchers from ISEV, ISAC and ISTH, worked together as an EV-FC WG and developed a consensus framework for the minimum information that should be provided regarding EV-FC. This framework incorporates the existing Minimum Information for Studies of EVs (MISEV) guidelines and Minimum Information about a FC experiment (MIFlowCyt) standard in an EV-FC-specific reporting framework (MIFlowCyt-EV) that supports reporting of critical information related to sample staining, EV detection and measurement and experimental design in manuscripts that report EV-FC data. MIFlowCyt-EV provides a structure for sharing EV-FC results, but it does not prescribe specific protocols, as there will continue to be rapid evolution of instruments and methods for the foreseeable future. MIFlowCyt-EV accommodates this evolution, while providing information needed to evaluate and compare different approaches. Because MIFlowCyt-EV will ensure consistency in the manner of reporting of EV-FC studies, over time we expect that adoption of MIFlowCyt-EV as a standard for reporting EV-FC studies will improve the ability to quantitatively compare results from different laboratories and to support the development of new instruments and assays for improved measurement of EVs.

**Date** 2020  
**Langue** eng  
**Titre abrégé** MIFlowCyt-EV  
**Catalogue de bibl.** PubMed  
**Extra** Number: 1  
**Volume** 9  
**Pages** 1713526  
**Publication** Journal of Extracellular Vesicles  
**DOI** [10.1080/20013078.2020.1713526](https://doi.org/10.1080/20013078.2020.1713526)

**Numéro** 1  
**Abrév. de revue** J Extracell Vesicles  
**ISSN** 2001-3078  
**Date d'ajout** 13/12/2021 à 10:36:14  
**Modifié le** 13/12/2021 à 10:36:14

- **Marqueurs :**
  - extracellular vesicles
  - Flow Cytometry
  - standardization
  - framework
  - reporting

### **Pièces jointes**

- PubMed entry
- Texte intégral
- **Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release**

**Type** Article de revue  
**Auteur** Audrey Benyamine  
**Auteur** Jérémy Magalon  
**Auteur** Florence Sabatier  
**Auteur** Luc Lyonnet  
**Auteur** Stéphane Robert  
**Auteur** Chloé Dumoulin  
**Auteur** Sophie Morange  
**Auteur** Karin Mazodier  
**Auteur** Gilles Kaplanski  
**Auteur** Martine Reynaud-Gaubert  
**Auteur** Pascal Rossi  
**Auteur** Françoise Dignat-George  
**Auteur** Brigitte Granel  
**Auteur** Pascale Paul

**Résumé** The pathophysiology of systemic sclerosis (SSc) involves early endothelial and immune activation, both preceding the onset of fibrosis. We previously identified soluble fractalkine and circulating endothelial microparticles (EMPs) as biomarkers of endothelial inflammatory activation in SSc. Fractalkine plays a dual role as a membrane-bound adhesion molecule expressed in inflamed endothelial cells (ECs) and as

a chemokine involved in the recruitment, transmigration, and cytotoxic activation of immune cells that express CX3CR1, the receptor of fractalkine, namely CD8 and  $\gamma\delta$  T cells and natural killer (NK) cells. We aimed to quantify circulating cytotoxic immune cells and their expression of CX3CR1. We further investigated the expression profile of NK cells chemokine receptors and activation markers and the potential of NK cells to induce EC activation in SSc. We performed a monocentric study (NCT 02636127) enrolling 15 SSc patients [15 females, median age of 55 years (39-63), 11 limited cutaneous form and 4 diffuse] and 15 healthy controls. Serum fractalkine levels were significantly increased in SSc patients. Circulating CD8 T cells numbers were decreased in SSc patients with no difference in their CX3CR1 expression. Circulating  $\gamma\delta$  T cells and NK cells numbers were preserved. CX3CR1 expression in CD8 and  $\gamma\delta$  T cells did not differ between SSc patients and controls. The percentage and level of CX3CR1 expression in NK cells were significantly lowered in SSc patients. Percentages of CXCR4, NKG2D, CD69-expressing NK cells, and their expression levels were decreased in NK cells. Conversely, CD16 level expression and percentages of CD16+ NK cells were preserved. The exposure of human microvascular dermic EC line (HMVEC-d) to peripheral blood mononuclear cells resulted in similar NK cells degranulation activity in SSc patients and controls. We further showed that NK cells purified from the blood of SSc patients induced enhanced release of EMPs than NK cells from controls. This study evidenced a peculiar NK cells phenotype in SSc characterized by decreased chemokine and activation receptors expression, that might reflect NK cells involvement in the pathogenic process. It also highlighted the role of NK cells as a potent mechanism inducing endothelial activation through enhanced EMPs release.

**Date** 2018  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Volume** 9  
**Pages** 1665  
**Publication** Frontiers in Immunology  
**DOI** [10.3389/fimmu.2018.01665](https://doi.org/10.3389/fimmu.2018.01665)  
**Abrév. de revue** Front Immunol  
**ISSN** 1664-3224  
**Date d'ajout** 13/12/2021 à 10:35:05  
**Modifié le** 13/12/2021 à 10:35:05

- **Marqueurs :**
  - CX3CR1
  - endothelial microparticles
  - fractalkine

- natural killer cells
- systemic sclerosis

## **Pièces jointes**

- PubMed entry
- Texte intégral

# **• Neutrophil extracellular traps are associated with the pathogenesis of diffuse alveolar hemorrhage in murine lupus**

<b>Type</b>	Article de revue
<b>Auteur</b>	Pierre-André Jarrot
<b>Auteur</b>	Edwige Tellier
<b>Auteur</b>	Lea Plantureux
<b>Auteur</b>	Lydie Crescence
<b>Auteur</b>	Stéphane Robert
<b>Auteur</b>	Corinne Chareyre
<b>Auteur</b>	Laurent Daniel
<b>Auteur</b>	Véronique Secq
<b>Auteur</b>	Stéphane Garcia
<b>Auteur</b>	Françoise Dignat-George
<b>Auteur</b>	Laurence Panicot-Dubois
<b>Auteur</b>	Christophe Dubois
<b>Auteur</b>	Gilles Kaplanski

## **Résumé**

Diffuse alveolar hemorrhage (DAH) is a life-threatening complication of systemic lupus erythematosus (SLE) and systemic vasculitis. Although initially described to have antibacterial properties, increasing evidence suggests that neutrophil extracellular traps (NETs) have a detrimental role in both autoimmune diseases and acute lung injury. We investigated whether NETs could be detected in a murine model of pristane-induced lupus DAH and contribute to lung injury. Such NETs might constitute a therapeutic target. NETs were characterized by immunofluorescence staining of DNA, neutrophil elastase and citrullinated histones. Evaluation of lung injury was performed by haematoxylin-eosin staining and a quantification program. Clinical status of the mice was assessed by measurement of arterial oxygen saturation and survival curves after recombinant human deoxyribonuclease-1 (Rh-DNase-1) inhalations or polymorphonuclear neutrophil (PMN) depletion. Pristane was found to promote NETs formation in vitro and in vivo. Treatment of mice with Rh-DNase-1 inhalations cleared NETs and reduced lung injury. Clinical status improved significantly, with increased arterial oxygenation and survival. Following PMN depletion, NETs were absent with a subsequent reduction of lung injury and improved arterial oxygenation.

These results support a pathogenic role of PMNs and NETs in lung injury during pristane-induced DAH. Targeting NETs with Rh-DNase-1 inhalations could constitute an interesting adjuvant therapy in human DAH.

**Date** Jun 2019  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Volume** 100  
**Pages** 120-130  
**Publication** Journal of Autoimmunity  
**DOI** [10.1016/j.jaut.2019.03.009](https://doi.org/10.1016/j.jaut.2019.03.009)  
**Abrév. de revue** J. Autoimmun.  
**ISSN** 1095-9157  
**Date d'ajout** 13/12/2021 à 10:34:50  
**Modifié le** 13/12/2021 à 10:34:50

- **Marqueurs :**
  - Neutrophil extracellular traps
  - Deoxyribonuclease-1
  - Diffuse alveolar hemorrhage
  - Murine model
  - Systemic lupus erythematosus

### **Pièces jointes**

- PubMed entry
- **Oral Squamous Cell Carcinoma Is Associated with a Low Thrombosis Risk Due to Storage Pool Deficiency in Platelets**

**Type** Article de revue  
**Auteur** Pierre Haen  
**Auteur** Lydie Crescence  
**Auteur** Diane Mege  
**Auteur** Alexandre Altié  
**Auteur** Christophe Dubois  
**Auteur** Laurence Panicot-Dubois

**Résumé** Venous thrombo-embolism (VTE) disease is the second most common cause of mortality in cancer patients, and evaluation and prevention of thrombosis risk is essential. VTE-associated risk varies according to the type of tumor disease. Oral cancer is the most frequent type of head and neck cancer, and it represents approximately 2.1% of all cancers

worldwide. Most tumors are squamous cell carcinomas and are mainly due to tobacco and alcohol abuse. VTE risk associated with oral squamous cell carcinoma (OSCC) is low. However, many studies have shown that OSCC has the following biological features of cancers associated with a high thrombosis risk: modified thrombosis and fibrinolysis mechanisms; strong expression of procoagulant proteins; secretion of procoagulant microparticles; and production of procoagulant cytokines. Using an original mouse model of tongue squamous cell carcinoma, our study aimed to clarify this paradoxical situation. First, we showed that OSCC tumors have a pro-aggregatory phenotype and a high local thrombosis risk. Second, we found that tongue tumor mice do not have an elevated systemic thrombosis risk (the risk of an "at distance" thrombosis event such as lower extremity deep venous thrombosis or pulmonary embolism) and even show a reduction in risk. Third, we demonstrated that tongue tumor mice show a reduction in platelet reactivity, which explains the low systemic thrombosis risk. Finally, we found that tongue tumor mice present granule pool deficiency, thereby explaining the reduction in platelet reactivity and systemic thrombosis risk.

**Date** 2021-02-24  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** Number: 3 PMID: 33668375 PMCID: PMC7996194  
**Volume** 9  
**Pages** 228  
**Publication** Biomedicines  
**DOI** [10.3390/biomedicines9030228](https://doi.org/10.3390/biomedicines9030228)  
**Numéro** 3  
**Abrév. de revue** Biomedicines  
**ISSN** 2227-9059  
**Date d'ajout** 13/12/2021 à 10:37:53  
**Modifié le** 13/12/2021 à 10:37:53

- **Marqueurs :**
  - disorders of platelet function
  - intravital microcopy
  - laser injury
  - oral squamous cancer
  - platelet granules

### **Pièces jointes**

- PubMed entry
- Texte intégral

## • Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination

**Type** Article de revue  
**Auteur** Akshita Sharma  
**Auteur** Ahmad Joshkon  
**Auteur** Aymen Ladjimi  
**Auteur** Waël Traboulsi  
**Auteur** Richard Bachelier  
**Auteur** Stéphane Robert  
**Auteur** Alexandrine Foucault-Bertaud  
**Auteur** Aurélie S. Leroyer  
**Auteur** Nathalie Bardin  
**Auteur** Indumathi Somasundaram  
**Auteur** Marcel Blot-Chabaud

**Résumé** Background: Triple Negative Breast Cancers (TNBC) are the most aggressive breast cancers and lead to poor prognoses. This is due to a high resistance to therapies, mainly because of the presence of Cancer Stem Cells (CSCs). Plasticity, a feature of CSCs, is acquired through the Epithelial to Mesenchymal Transition (EMT), a process that has been recently shown to be regulated by a key molecule, CD146. Of interest, CD146 is over-expressed in TNBC. Methods: The MDA-MB-231 TNBC cell line was used as a model to study the role of CD146 and its secreted soluble form (sCD146) in the development and dissemination of TNBC using in vitro and in vivo studies. Results: High expression of CD146 in a majority of MDA-MB-231 cells leads to an increased secretion of sCD146 that up-regulates the expression of EMT and CSC markers on the cells. These effects can be blocked with a specific anti-sCD146 antibody, M2J-1 mAb. M2J-1 mAb was able to reduce tumour development and dissemination in a model of cells xenografted in nude mice and an experimental model of metastasis, respectively, in part through its effects on CSC. Conclusion: We propose that M2J-1 mAb could be used as an additional therapeutic approach to fight TNBC.

**Date** 2022/1

**Langue** en

**Catalogue de bibl.** [www.mdpi.com](http://www.mdpi.com)

**URL** <https://www.mdpi.com/1422-0067/23/2/974>

**Consulté le** 17/01/2022 à 10:38:09

**Autorisations** <http://creativecommons.org/licenses/by/3.0/>

**Extra** Number: 2 Publisher: Multidisciplinary Digital Publishing Institute

**Volume** 23

**Pages** 974  
**Publication** International Journal of Molecular Sciences  
**DOI** [10.3390/ijms23020974](https://doi.org/10.3390/ijms23020974)  
**Numéro** 2  
**Date d'ajout** 17/01/2022 à 10:38:09  
**Modifié le** 17/01/2022 à 10:38:09

- **Marqueurs :**
  - CD146
  - treatment
  - triple negative breast cancer

### **Pièces jointes**

- Full Text PDF
- Snapshot

- **The Interaction of Platelets with Colorectal Cancer Cells Inhibits Tumor Growth but Promotes Metastasis**

**Type** Article de revue  
**Auteur** Léa Plantureux  
**Auteur** Diane Mège  
**Auteur** Lydie Crescence  
**Auteur** Estelle Carminita  
**Auteur** Stéphane Robert  
**Auteur** Sylvie Cointe  
**Auteur** Nicolas Brouilly  
**Auteur** Walid Ezzedine  
**Auteur** Françoise Dignat-George  
**Auteur** Christophe Dubois  
**Auteur** Laurence Panicot-Dubois

**Résumé** Platelets promote metastasis, however, their role in tumor growth remains controversial. Here, we investigated the effect of platelet interactions with colorectal tumor cells. Platelets extravasated into the tumor microenvironment and interacted with tumor cells in a cadherin-6-dependent manner. The interaction induced platelet spreading, release of their granule content, and the generation of three types of microparticles (iMP) that expressed platelet markers, tumor markers, or both. The presence of iMPs was confirmed in colorectal cancer tissue specimens. Platelets significantly reduced tumor growth and increased intratumoral macrophages. This was mediated by iMP recruitment of macrophages via the chemoattractants RANTES, MIF, CCL2, and CXCL12 and activation of their tumor cell killing capacity through

IFN $\gamma$  and IL4, which led to cell-cycle arrest of tumor cells in a p21-dependent manner. In contrast, in the bloodstream, iMPs activated endothelial cells and platelets and induced epithelial-to-mesenchymal transition of tumor cells, promoting metastasis. Altogether, these results indicate that depending on the environment, local or bloodstream, the consequences of the interactions between platelets and a tumor may promote or prevent cancer progression. **SIGNIFICANCE:** Tumor cell interaction with platelets produces chimeric extracellular vesicles that suppress primary tumor growth by activating tumor-eliminating macrophages, while promoting metastasis through EMT and endothelial activation.

**Date** Jan 15, 2020  
**Langue** eng  
**Catalogue de bibl.** PubMed  
**Extra** Number: 2  
**Volume** 80  
**Pages** 291-303  
**Publication** Cancer Research  
**DOI** [10.1158/0008-5472.CAN-19-1181](https://doi.org/10.1158/0008-5472.CAN-19-1181)  
**Numéro** 2  
**Abrév. de revue** Cancer Res.  
**ISSN** 1538-7445  
**Date d'ajout** 13/12/2021 à 10:36:31  
**Modifié le** 13/12/2021 à 10:36:31

- **Pièces jointes**
  - PubMed entry